NCT07245056 Fetal Fornix and Hippocampus in Pregnant Women With Early-Onset Preeclampsia
| NCT ID | NCT07245056 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ankara Etlik City Hospital |
| Condition | Pre-Eclampsia |
| Study Type | INTERVENTIONAL |
| Enrollment | 84 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 84 participants in total. It began in 2025-12-01 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Since early-onset preeclampsia (EOPE) is commonly associated with inadequate placentation, placental insufficiency, chronic fetal hypoxia, oxidative stress, and heightened inflammation, these pathological processes may adversely affect hippocampal neuronal development and maturation of axonal pathways such as the fornix. These mechanisms support our hypothesis that fetal fornix and hippocampus dimensions may be reduced in pregnancies complicated by EOPE, forming the scientific basis of our study. Previous research has suggested a potential link between preeclampsia (PE) and altered neurocognitive development. However, no studies to date have specifically evaluated the relationship between EOPE and fetal fornix or hippocampus dimensions. Therefore, the objective of our study is to assess fetal fornix and hippocampus measurements in pregnant women with early-onset preeclampsia compared with healthy controls.
Eligibility Criteria
Inclusion Criteria: * Women aged 18-45 years * Gestational age between 20 and 34 weeks * Diagnosis of early-onset preeclampsia (EOPE) * Singleton pregnancy Exclusion Criteria: * Multiple pregnancies * Presence of chronic or significant comorbid conditions other than maternal early-onset preeclampsia, including: Chronic, mental, or physical illnesses, severe renal, hepatic, or gastrointestinal acute or chronic inflammatory diseases, hyperthyroidism or hypothyroidism, chronic hypertension, type 1 or type 2 diabetes mellitus, history of polycystic ovary syndrome (PCOS), history of malignancy * Fetal congenital or chromosomal anomalies * Chronic medication use * Tobacco or alcohol use during pregnancy * Maternal late-onset preeclampsia (≥34 weeks gestation)
Contact & Investigator
Seyit A Erol, MD
PRINCIPAL INVESTIGATOR
Ankara Etlik City Hospital
Frequently Asked Questions
Who can join the NCT07245056 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Pre-Eclampsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07245056 currently recruiting?
Yes, NCT07245056 is actively recruiting participants. Contact the research team at gyn.aerol@gmail.com for enrollment information.
Where is the NCT07245056 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye).
Who is sponsoring the NCT07245056 clinical trial?
NCT07245056 is sponsored by Ankara Etlik City Hospital. The principal investigator is Seyit A Erol, MD at Ankara Etlik City Hospital. The trial plans to enroll 84 participants.